Lightstone Ventures

Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.

Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. The company specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. Its flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on individualized peripheral nerve stimulation to enhance patient outcomes. In addition to its work on essential tremor, the company is also developing therapies for conditions such as Parkinson's disease, as well as exploring applications in psychiatry, cardiology, and autoimmune disorders.

Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.

Willow Inc., established in 2014 and headquartered in Mountain View, California, specializes in the manufacture of wearable breast pumps for women. The company offers a range of products including milk bags, accessories such as flanges and tubes, and replacement parts. Willow's flagship product is an in-bra wearable breast pump designed to provide mothers with mobility and hands-free convenience during breastfeeding. The company also provides pumping bras, cases, and other breastfeeding essentials.

Willow Inc., established in 2014 and headquartered in Mountain View, California, specializes in the manufacture of wearable breast pumps for women. The company offers a range of products including milk bags, accessories such as flanges and tubes, and replacement parts. Willow's flagship product is an in-bra wearable breast pump designed to provide mothers with mobility and hands-free convenience during breastfeeding. The company also provides pumping bras, cases, and other breastfeeding essentials.

Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. The company specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. Its flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on individualized peripheral nerve stimulation to enhance patient outcomes. In addition to its work on essential tremor, the company is also developing therapies for conditions such as Parkinson's disease, as well as exploring applications in psychiatry, cardiology, and autoimmune disorders.

Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.

Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.

Cala Health, Inc. is a bioelectronic medicine company based in Burlingame, California, founded in 2013. The company specializes in developing wearable neuromodulation therapies aimed at treating chronic diseases. Its flagship product, Cala Trio, is a non-invasive prescription therapy designed to provide transient relief from hand tremors in adults with essential tremor. By integrating advancements in neuroscience and technology, Cala Health focuses on individualized peripheral nerve stimulation to enhance patient outcomes. In addition to its work on essential tremor, the company is also developing therapies for conditions such as Parkinson's disease, as well as exploring applications in psychiatry, cardiology, and autoimmune disorders.

Fire1 is a Dublin-based company dedicated to developing innovative therapeutic devices aimed at enhancing the quality of life for heart failure patients. The company has created a remote monitoring system that delivers real-time patient data and insights to healthcare providers. This technology facilitates the early detection of complications associated with heart failure, allowing for proactive interventions and ultimately leading to improved patient outcomes. Through its focus on remote monitoring, Fire1 seeks to transform the management of heart failure and support better health management for patients.